Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.

Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH.

J Biol Chem. 2007 Aug 31;282(35):25604-12. Epub 2007 Jun 28.

2.

The functions of mTOR in ischemic diseases.

Hwang SK, Kim HH.

BMB Rep. 2011 Aug;44(8):506-11. Review.

3.

Growing knowledge of the mTOR signaling network.

Huang K, Fingar DC.

Semin Cell Dev Biol. 2014 Dec;36:79-90. doi: 10.1016/j.semcdb.2014.09.011. Epub 2014 Sep 19. Review.

4.

mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.

Bracho-Valdés I, Moreno-Alvarez P, Valencia-Martínez I, Robles-Molina E, Chávez-Vargas L, Vázquez-Prado J.

IUBMB Life. 2011 Oct;63(10):896-914. doi: 10.1002/iub.558. Epub 2011 Sep 9. Review.

5.

mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.

Wysocki PJ.

Expert Rev Mol Diagn. 2009 Apr;9(3):231-41. doi: 10.1586/erm.09.8. Review.

PMID:
19379082
6.

Targeting the mTOR pathway in tumor malignancy.

Cheng H, Walls M, Baxi SM, Yin MJ.

Curr Cancer Drug Targets. 2013 Mar;13(3):267-77. Review.

PMID:
23297825
7.

Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.

Wang H, Zhang Q, Wen Q, Zheng Y, Lazarovici P, Jiang H, Lin J, Zheng W.

Cell Signal. 2012 Jan;24(1):17-24. doi: 10.1016/j.cellsig.2011.08.010. Epub 2011 Aug 31. Review. Erratum in: Cell Signal. 2012 Nov;24(11):2226. Philip, Lazarovici [corrected to Lazarovici, Philip].

PMID:
21906675
8.

Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.

Zou Z, Chen J, Yang J, Bai X.

Curr Cancer Drug Targets. 2016;16(4):288-304. Review.

PMID:
26563881
9.

The complexes of mammalian target of rapamycin.

Zhou H, Huang S.

Curr Protein Pept Sci. 2010 Sep;11(6):409-24. Review.

10.

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K.

Oxid Med Cell Longev. 2010 Nov-Dec;3(6):374-91. Epub 2010 Nov 1. Review.

11.

Phosphorylation of Akt at the C-terminal tail triggers Akt activation.

Liu P, Wang Z, Wei W.

Cell Cycle. 2014;13(14):2162-4. doi: 10.4161/cc.29584. Epub 2014 Jun 16. Review.

12.

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy.

Choo AY, Blenis J.

Cell Cycle. 2009 Feb 15;8(4):567-72. Epub 2009 Feb 18. Review.

PMID:
19197153
13.

A complex interplay between Akt, TSC2 and the two mTOR complexes.

Huang J, Manning BD.

Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22. doi: 10.1042/BST0370217. Review.

14.

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.

Shaw RJ.

Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19. Review.

15.

Raptor and mTOR: subunits of a nutrient-sensitive complex.

Kim DH, Sabatini DM.

Curr Top Microbiol Immunol. 2004;279:259-70. Review.

PMID:
14560962
16.

Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells.

Jhanwar-Uniyal M, Jeevan D, Neil J, Shannon C, Albert L, Murali R.

Adv Biol Regul. 2013 May;53(2):202-10. doi: 10.1016/j.jbior.2012.10.001. Epub 2012 Oct 26. Review.

PMID:
23231881
17.

Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease.

Leo MS, Sivamani RK.

Arch Dermatol Res. 2014 Dec;306(10):861-71. doi: 10.1007/s00403-014-1480-8. Epub 2014 Jun 28. Review.

PMID:
24972910
18.

Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2).

Destefano MA, Jacinto E.

Biochem Soc Trans. 2013 Aug;41(4):896-901. doi: 10.1042/BST20130018. Review.

19.

Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.

Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R.

Adv Biol Regul. 2017 May;64:39-48. doi: 10.1016/j.jbior.2016.12.001. Epub 2017 Jan 4. Review.

PMID:
28189457
20.

AMPK and mTOR in cellular energy homeostasis and drug targets.

Inoki K, Kim J, Guan KL.

Annu Rev Pharmacol Toxicol. 2012;52:381-400. doi: 10.1146/annurev-pharmtox-010611-134537. Epub 2011 Oct 17. Review.

PMID:
22017684

Supplemental Content

Support Center